| 1 |
33764811 | Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin. | 2022 Feb |
2 |
| 2 |
33399940 | Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair. | 2021 Feb |
1 |
| 3 |
33422766 | Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. | 2021 Feb |
7 |
| 4 |
33952496 | ERCC1 Is a Predictive Biomarker for Non-small Cell Lung Cancer But Is Antibody-dependent. | 2021 May |
1 |
| 5 |
34148553 | ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis. | 2021 Jun 21 |
2 |
| 6 |
34320692 | Benzo[a]pyrene diol epoxide-induced transformed cells identify the significance of hsa_circ_0051488, a ERCC1-derived circular RNA in pulmonary squamous cell carcinoma. | 2021 Oct |
1 |
| 7 |
34414935 | Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis. | 2021 Aug 20 |
4 |
| 8 |
34898581 | ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer Group. | 2021 Nov 5 |
2 |
| 9 |
31815582 | Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201. | 2020 Feb 10 |
1 |
| 10 |
31891209 | Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction. | 2020 Apr |
1 |
| 11 |
31958797 | Predictive Value of Excision Repair Cross-Complementation Group 1 in the Response to Platinum-Based Chemotherapy in Esophageal Cancer: A Meta-Analysis. | 2020 |
7 |
| 12 |
32008866 | ERCC1 expression in advanced colorectal cancer and matched liver metastases. | 2020 Mar |
1 |
| 13 |
32167697 | Evaluation of nuclear NF-κB, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors. | 2020 May-Jun |
3 |
| 14 |
32344513 | Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy. | 2020 Apr 24 |
3 |
| 15 |
32419821 | Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer. | 2020 |
2 |
| 16 |
32711417 | ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy. | 2020 Jul 1 |
4 |
| 17 |
32738410 | Design, synthesis and in vitro cell-free/cell-based biological evaluations of novel ERCC1-XPF inhibitors targeting DNA repair pathway. | 2020 Oct 15 |
1 |
| 18 |
32847049 | Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts. | 2020 Aug 24 |
2 |
| 19 |
32880833 | Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh. | 2020 Sep |
1 |
| 20 |
32963615 | Demethoxycurcumin increases the sensitivity of cisplatin-resistant non-small lung cancer cells to cisplatin and induces apoptosis by activating the caspase signaling pathway. | 2020 Nov |
1 |
| 21 |
33148925 | Significance of ERCC1 and Hormonal Receptor Expression in Ovarian Cancer. | 2020 |
4 |
| 22 |
33154302 | Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients. | 2020 Oct-Dec |
2 |
| 23 |
33266377 | Clinical Perspectives of ERCC1 in Bladder Cancer. | 2020 Nov 22 |
1 |
| 24 |
29662106 | Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. | 2019 Apr |
2 |
| 25 |
30538112 | Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer. | 2019 Apr 15 |
2 |
| 26 |
30584903 | Integrative PDGF/PDGFR and focal adhesion pathways are downregulated in ERCC1-defective non-small cell lung cancer undergoing sodium glycididazole-sensitized cisplatin treatment. | 2019 Apr 5 |
8 |
| 27 |
30628188 | Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA. | 2019 Mar |
2 |
| 28 |
30668408 | Demethoxycurcumin sensitizes the response of non-small cell lung cancer to cisplatin through downregulation of TP and ERCC1-related pathways. | 2019 Feb |
1 |
| 29 |
30797591 | ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers. | 2019 May |
6 |
| 30 |
30973677 | Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment. | 2019 Aug |
1 |
| 31 |
31169219 | Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma? | 2019 Jul-Sep |
2 |
| 32 |
31333777 | AC138128.1 an Intronic lncRNA originating from ERCC1 Implies a Potential Application in Lung Cancer Treatment. | 2019 |
1 |
| 33 |
31369707 | Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF. | 2019 Sep 12 |
1 |
| 34 |
31521181 | Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study. | 2019 Sep 14 |
5 |
| 35 |
31565185 | Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin. | 2019 Sep 17 |
1 |
| 36 |
31602266 | Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer. | 2019 |
2 |
| 37 |
32184881 | Study of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers. | 2019 Fall |
1 |
| 38 |
29187510 | ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. | 2018 Feb |
3 |
| 39 |
29226731 | Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1. | 2018 Jan |
2 |
| 40 |
29491212 | Association of DNA Repair and Drug Transporter in Relation to Chemosensitivity in Primary Culture of Thai Gastric Cancer Patients. | 2018 |
2 |
| 41 |
29572009 | Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum. | 2018 Apr |
1 |
| 42 |
29710850 | Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease. | 2018 Apr 30 |
1 |
| 43 |
29861877 | SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. | 2018 May 18 |
1 |
| 44 |
29905882 | ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer. | 2018 Jun 15 |
2 |
| 45 |
30048976 | Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells. | 2018 |
2 |
| 46 |
30194007 | Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer. | 2018 Nov |
2 |
| 47 |
27737534 | ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer. | 2017 Jul |
2 |
| 48 |
27893323 | ERCC1 as Predictor of Platinum Benefit in Non-Small-Cell Lung Cancer. | 2017 Feb |
1 |
| 49 |
27893326 | Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). | 2017 Feb |
3 |
| 50 |
28102711 | Higher Expression of ERCC1 May Be Associated with Resistance to Adjuvant Platinum-Based Chemotherapy in Gastric Cancer. | 2017 Feb 7 |
3 |